Table 1.
Characteristics of the 2,296 injection drug users screend from the San Francisco Bay area, between 1998–2000.
| Characteristic (No. subjects with missing data) | Median | IQRa |
|---|---|---|
| Age at enrollment | 45 | [38–49] |
| Years of injection drug use (59) | 24 | [15–31] |
| No. | % | |
| Gender (31) | ||
| Male | 1608 | 71.0% |
| Female | 657 | 29.0% |
| Race | ||
| White | 869 | 37.8% |
| African American | 1136 | 49.5% |
| Latino | 164 | 7.1% |
| Others | 127 | 5.5% |
| Hepatitis B virus infectionb | ||
| Anti-HBc positive (ever infected) | 1764 | 80.5% |
| HBsAg positive (currently infected) | 73 | |
| Anti-HBc IgM positive (acutely infected) | 19 | |
| Anti-HBc IgM negative (chronically infected) | 54 | |
| HBsAg negative (resolved infection) | 1691 | |
| Anti-HBc and anti-HBs negative (never infected) | 426 | 19.5% |
| Hepatitis C virus infection | ||
| Anti-HCV positive (ever infected) | 2092 | 91.1% |
| HCV RNA positive (chronically infected) | 1717 | |
| HCV RNA negative (resolved infection) | 375 | |
| Anti-HCV negative (never infected) | 204 | 8.9% |
| HIV-1 infection (3) | 273 | 11.9% |
a
IQR: inter-quartile range
b
Subjects with serologic evidence of vaccination for HBV (n=106), defined by the presence of anti- HBs and the absence of anti-HBc, were excluded.